The role of the Committees within TTS are extremely important to ensure the ongoing development of our Society and make certain that it continues to meet the needs to our membership. As such, it is important that we have a good representation on each committee to address the varied needs of our membership, whether from a geographic, gender or role perspective.
In reviewed the composition of our Committees, we find that the vast majority have good, balanced representation. However, some Committees would benefit from increased diversity, particularly from a geographic standpoint. As such, we are seeking self-nominations to participate in the following Committees: Heart and Lung Committee, Membership Committee and Young Members Committee
Though we have identified needs for additional geographic representation based on the above criteria, we welcome any self-nominations. The Committee Chairs will review the self-nominations to ensure a complete and balanced Committee.
The only expectation of nominees is that they actively participate in committee activities and lead the work of their committee within their respective regions.
Every two years, the ISODP Congress brings together clinicians and scientists from all parts of the world in the fields of organ procurement and donation
A number of transplant organizations from around the world continue their partnership to create a fourth educational webinar for the organ donation and transplantation communities. Our goal is to share experiences to date and respond to your questions about the impact of COVID-19 on organ donation and transplantation.
Talks will include:
Special Thanks To:
Dr. Jeremy R. Chapman, Editor-in-Chief, Transplantation
Transplantation: October 29, 2020 - Volume Online First
This useful summary of the therapeutic approaches to COVID-19 in transplant populations separates the early weeks and months when data were lacking in both the general and organ transplant populations from the later era as data became available. The first era involved use of drugs such as hydroxychloroquine with or without azithromycin, lopinavir-ritonavir, and tocilizumab with little or no effect. With the publication of larger trials, remdesivir, dexamethasone, and convalescent plasma have been advised. There is now a large number of clinical trials of investigational and repurposed agents with antiviral or immunomodulatory effects. This organ transplant focussed overview will help those working to contain the impact of the current waves of COVID-19 globally.
Therapies to interrupt progression of early COVID-19 remain elusive. Among them, convalescent plasma in hospitalized patients was unsuccessful, perhaps because antibody should be administered earlier. A randomized, double-blind, placebo-controlled trial of convalescent plasma with high IgG titers against SARS-CoV2 in elderly subjects within 72 hours of mild COVID-19 symptoms. The primary endpoint was severe respiratory disease defined as a respiratory rate ≥30 and/or an O2 sat<93% in room air. 160 patients underwent randomization. In the intention-to-treat analysis (ITT), 13/80(16.2%) patients receiving plasma vs. 25/80(31.2%) receiving placebo experienced severe respiratory disease [RR(95%CI)= 0.52(0.29,0.94); p=0.026)] with an RRR=48%. High- and low-titer donor analyses, based on a median IgG titer=1:3,200, evidenced a dose-dependent response with an RRR=73.3% for recipients of high-titer plasma (p=0.016) and a number needed to treat (NNT)=4.4. All secondary endpoints exhibited trends towards protection. No solicited adverse events were observed. Early administration of high-titer convalescent plasma against SARSCoV2 to mildly ill infected seniors reduced COVID-19 progression.
In this repeated, cross-sectional study of 177 919 residual clinical specimens, the estimated percentage of persons in a jurisdiction with detectable SARS-CoV-2 antibodies ranged from fewer than 1% to 23%. Over 4 sampling periods in 42 of 49 jurisdictions with calculated estimates, fewer than 10% of people had detectable SARS-CoV-2 antibodies.
In this study, A total of 228 patients were assigned to receive convalescent plasma and 105 to receive placebo. The median time from the onset of symptoms to enrollment in the trial was 8 days (interquartile range, 5 to 10), and hypoxemia was the most frequent severity criterion for enrollment. The infused convalescent plasma had a median titer of 1:3200 of total SARS-CoV-2 antibodies (interquartile range, 1:800 to 1:3200]. At day 30 day, no significant difference was noted between the convalescent plasma group and the placebo group in the distribution of clinical outcomes according to the ordinal scale (odds ratio, 0.83 (95% confidence interval [CI], 0.52 to 1.35; P=0.46). Overall mortality was 10.96% in the convalescent plasma group and 11.43% in the placebo group, for a risk difference of −0.46 percentage points (95% CI, −7.8 to 6.8). Total SARS-CoV-2 antibody titers tended to be higher in the convalescent plasma group at day 2 after the intervention. Adverse events and serious adverse events were similar in the two groups.
The Transplantation Society (TTS) and our journal Transplantation have developed online resources to keep you informed on the Coronavirus (COVID-19) outbreak.
We are also requesting contributions and news from the transplant community to be sent to firstname.lastname@example.org for inclusion on our resources page.
In this dashboard, you will find links to TTS and other global and regional resources, as well as interactive maps, publications and webinars. We encourage you to explore this dashboard and share with your colleagues.
Editors and contributors to Transplantation have shared their thoughts on how they are dealing with the current crisis. While we understand that the information of today may be quite different tomorrow in this fast-moving pandemic, this report will open our forum of an international exchange on COVID for the transplant community.
Please send your own contributions and news to email@example.com for inclusion on our resources page.
Nov. 24 - Since liver transplantation following cDCD is correlated with higher rates of graft loss, researchers sought to compare HOPE and NRP in liver transplantation from cDCD. They evaluated outcomes after cDCD liver transplantation in 1 Swiss (HOPE) and 6 French (NRP) centers in this retrospective comparative cohort study.
Nov. 24 - When it comes to organ transplants, there is no time to lose trying to find a medical flight. In order to simplify and expedite the process, what is needed is a centralized network hub that can work out all the details, explains Sim Shain, CEO and Founder of ParaFlight EMS and Aviation, and OrganFlights.com.
Nov. 24 - By using a technology involving a process similar to 3D printing, Australian researchers have produced a large number of man-made tiny kidneys with stable quality, taking one step closer to the reality of bio-printed kidney for human organ transplantation.
Nov. 25 - An international research group has clarified the action mechanism of incretin-based drugs in the treatment of diabetes. Incretin-based drugs are used worldwide in the treatment of diabetes and in Japan they are currently prescribed to 70% of diabetic patients. However, the mechanism by which incretin-based drugs improve blood glucose levels has been poorly understood.